TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

December 31, 2023

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
COMBINATION_PRODUCT

Nivolumab

hepatic artery infusion therapy with nivolumab was performed

PROCEDURE

Transarterial Chemoembolization (TACE)

Seldinger technique for femoral artery puncture. Catheterization to celiac trunk/hepatic artery. Infusion of a mixture of idarubicin, raltitrexed, iodized oil, and contrast agent (approx. 8 mL). Embolization with microspheres (300-500 μm and 500-700 μm).

Trial Locations (1)

050031

The First Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

The First Hospital of Hebei Medical University

OTHER

NCT07053202 - TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter